TY - JOUR T1 -长效抗毒蕈碱药物(LAMA)在现实生活中严重哮喘患者的使用频率和临床特征:数据来自意大利严重哮喘网络(SANI)注册中心JF -欧洲呼吸杂志JO - Eur Respir J DO - 10.1183/13993003.congress-2019。PA4255六世- 54 - 5 63 SP - PA4255盟Puggioni弗朗西斯卡盟——Heffler Enrico马可AU - Canonica,乔治•沃尔特盟——Latorre曼非盟-布拉西,弗朗西斯科·盟——Paggiaro Pierluigi盟——Caminati马可AU -塞纳,Gianenrico Y1 - 2019/09/28 UR - //www.qdcxjkg.com/content/54/suppl_63/PA4255.abstract N2 -背景:不受控制的哮喘患者尽管高剂量吸入激素加上另一个控制器被定义为严重的哮喘患者。噻托溴铵Respimat是唯一批准用于严重哮喘的长效毒蕈碱激动剂(LAMA)。目的:探讨重度哮喘患者接受LAMAs治疗的频率，并在现实生活中描述其临床特征。方法:分析来自意大利严重哮喘网络(SANI)注册的基线数据，以研究LAMA在严重哮喘患者中的使用及其可能的临床特征。结果:在总共698名入选患者中，35.9%的患者接受LAMAs治疗(23.3%溴化噻托溴铵Respimat, 4.5%溴化噻托溴铵Handihaler, 4.5%阿克定宁，3.4%溴化甘曲溴铵0,3%溴化美克定溴铵)。服用LAMAs的患者哮喘发病年龄较高(35.3 vs 32.4, p=0.045)，且既往吸烟者较多(26.6% vs 17.5%， p=0.001)。他们有更高的年加重率(3.9 vs 2.4, p=0.004)，哮喘控制最差(ACT: 17.2 vs 18.4, p=0.012;ACQ: 2.88 vs 2.47, p=0.008)，疾病相关生活质量最差(AQLQ: 4.24 vs 4.69, p=0.001)，肺功能较差(FEV1%: 70.26% vs 75.48%， p=0.007)。LAMA使用者更易发现支气管扩张(25.9% vs 13.1%， p=0.001)。 Patients taking LAMAs were also more frequently treated also with biologicals (64.4% vs 54.5%, p=0.011).Conclusions: Tiotropium bromide is still underused in severe asthma in a real-life setting. Patients taking LAMAs have features of the most severe asthmaticsFootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4255.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -